Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer

23 Jan 2019

Abstract excerpt

HER2 remains a therapeutic target in drug-resistant HER2-positive breast cancer, and a recombinant human protein overcomes the drug resistance.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30674653
DOI: 10.1126/scitranslmed.aav1620

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancerPMID 30674653Read ↗

Targeting the function of the HER2 oncogene in human cancer therapeuticsSemantic proximity Read ↗

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read ↗

The human epidermal growth factor receptor 2 (HER2)Semantic proximity Read ↗

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistanceSemantic proximity Read ↗

Bioactivity of Recombinant Humanized Monoclonal Antibody Against HER2 and Its Mechanism of Action on Ovarian CancerSemantic proximity Read ↗

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancerSemantic proximity Read ↗

Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast CancerSemantic proximity Read ↗

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugsSemantic proximity Read ↗

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers.Semantic proximity Read ↗

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabSemantic proximity Read ↗

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocksSemantic proximity Read ↗

PROTACs as Potential Therapeutic Agents for Cancer Drug ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.